ArticleReceptors & clinical investigation
Implications of scavenger receptors in the safe development of nanotherapeutics.
Article in Receptors & clinical investigation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Multivalent Co-assembly of LL37-CpG nanoparticles: Enhanced immune response through activating multiple cell internalization pathways.Materials today. Bio · 2025Article
- The regulation of NFKB1 on CD200R1 expression and their potential roles in Parkinson's disease.Journal of neuroinflammation · 2024Article
- Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands.Journal of nanobiotechnology · 2024Review
- Liposome-Mediated Anti-Viral Drug Delivery Across Blood-Brain Barrier: Can Lipid Droplet Target Be Game Changers?Cellular and molecular neurobiology · 2023Review
- Influence of Impurities from Manufacturing Process on the Toxicity Profile of Boron Nitride Nanotubes.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System.Pharmaceutics · 2022Review
- Defining Endocytic Pathways of Fucoidan-Coated PIBCA Nanoparticles from the Design of their Surface Architecture.Pharmaceutical research · 2022Article
- Mechanisms Involved in Microglial-Interceded Alzheimer's Disease and Nanocarrier-Based Treatment Approaches.Journal of personalized medicine · 2021Review
- Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).International journal of molecular sciences · 2021Review
- Insights into Multifunctional Nanoparticle-Based Drug Delivery Systems for Glioblastoma Treatment.Molecules (Basel, Switzerland) · 2021Review
- Tailoring Iron Oxide Nanoparticles for Efficient Cellular Internalization and Endosomal Escape.Nanomaterials (Basel, Switzerland) · 2020Review
- Microglia-targeting nanotherapeutics for neurodegenerative diseases.APL bioengineering · 2020Article
- Cell Membrane-Based Biomimetic Nanoparticles and the Immune System: Immunomodulatory Interactions to Therapeutic Applications.Frontiers in bioengineering and biotechnology · 2020Review
- Nanovaccines for cancer immunotherapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Cellular internalization of bystander nanomaterial induced by TAT-nanoparticles and regulated by extracellular cysteine.Nature communications · 2019Article
- Peptosome Coadministration Improves Nanoparticle Delivery to Tumors through NRP1-Mediated Co-Endocytosis.Biomolecules · 2019Article
- Engineered nanomaterials and oxidative stress: current understanding and future challenges.Current opinion in toxicology · 2019Article
- Biomimetic Nanoparticle Vaccines for Cancer Therapy.Advanced biosystems · 2019Article
- Experimental challenges regarding the in vitro investigation of the nanoparticle-biocorona in disease states.Toxicology in vitro : an international journal published in association with BIBRA · 2018Article
- Unintended effects of drug carriers: Big issues of small particles.Advanced drug delivery reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Nanomaterials (NMs) are being utilized in a variety of biomedical applications including drug delivery, diagnostics, and therapeutic targeting. These applications are made possible due to the unique physicochemical properties that are exhibited at the nanoscale. To ensure safe development of NMs for clinical use, it is necessary to understand their interactions with cells and specifically cell surface receptors, which will facilitate either their toxicity and/or clinical function. Recently our research and others have investigated the role of scavenger receptors in mediating NM-cell interactions and responses. Scavenger receptors are expressed by a variety of cell types that are first to encounter NMs during clinical use such as macrophages and endothelial cells. Scavenger receptors are recognized to facilitate uptake of a wide variety of ligands ranging from foreign substances to endogenous lipids/proteins. While interaction of NMs with scavenger receptors may allow therapeutic targeting in some instances, it also presents a challenge for the stealth delivery of NMs and avoidance of the scavenging capability of this class of receptors. Due to their role in facilitating immune responses, scavenger receptor-mediated inflammation is also of concern following NM delivery. The research highlighted in this brief review intends to summarize our current understanding regarding the consequences of NM-scavenger receptor interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.